It is possible that aspirin may reduce low-grade inflammation associated with age-related bone fragility. However, previous studies have been inconsistent about the effect of aspirin on bones.
The ASPREE-Fracture sub-study will determine whether daily low-dose aspirin reduces the risk of older Australians having a bone fracture. It will also investigate whether aspirin reduces the risk of having a fall that results in hospital attendance.
The ASPREE-Fracture sub-study is the first double-blind, randomised, placebo-controlled trial of aspirin and fracture risk in healthy older people.
What does participation involve?
This study collects relevant information entirely through medical records. If a participant has sustained a fracture, or attended a hospital or emergency department because of a fall since enrolling in the trial, we will follow up with their health provider to collect information about the fracture and/or treatment.
Results will be collated in 2017 to determine whether a daily low dose of aspirin can prevent or reduce the number of fractures and fall-related hospital presentations experienced by older people.
How to find out more about the ASPREE-FRACTURE study:
- Ring 1800 728 745 (toll free from a landline)
- Monash University
- University of Melbourne
- Western Health
- Austin Health
- The Mayo Clinic, USA
- University of Sydney
- Deakin University
- Co-investigating GPs
- The Australian National Health and Medical Research Council (NHMRC)